This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Tetsuzo Agishi, MD, PhD
Tokyo Women's Medical College Tokyo, Japan

JAMA. 1995;273(7):521.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Marked elevation of bradykinin concentration in contact with a polysulfone plasma separator, the membrane material of which is also charged negative, has been reported by Koga et al.¹ Administration of an ACE inhibitor during LDL adsorption with a DSC must be done with extreme care, according to an official notice from the Japanese Ministry of Health and Welfare, distributed October 21, 1993.

Recently, Sinzinger et al² reported data concluding that use of ACE inhibitors with a shorter half-life or withdrawal of the compounds more than 24 hours before LDL apheresis is not safe enough.

As we noted in our original letter, the protease inhibitor nafamostat mesylate (FUTHAN, Torii Pharmaceutical Co Ltd, Tokyo, Japan), which is widely used as an anticoagulant for extracorporeal circulation but currently commercially available only in Japan, is known to inhibit release and accumulation of bradykinin even with concomitant administration of ACE inhibitors. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?